Higher plants are a source of thousands of natural products, with an almost infinite variety of different structural variations. These molecules often have specific functions and many of them have biological activities which can be of use to humans. They may provide lead compounds for the development of new drugs or they may be indispensable tools in biomedical research.
Medicinal plants have always had an important place in the therapeutic armoury of mankind. Up to 80% of populations in developing countries are totally dependent on plants for their primary health care. Moreover, despite the remarkable progress in synthetic organic chemistry of the twentieth century, over 25% of prescribed medicines in industrialised countries derive either directly or indirectly from plants [1] . This percentage can reach 50% when the over-the-counter (OTC) market is taken into consideration.
In this context, and in view of the rapid disappearance of tropical forests and other important areas of vegetation, there is good reason to pursue research in the domain of plants. Urgent attention has to be paid to as many as possible of the estimated 350,000 plant species on earth, a large percentage of which still have not been investigated for their phytochemical and pharmacological potential. This green inheritance thus represents an enormous reservoir of putative lead compounds with an almost infinite variety of different structural variations [2] waiting to be discovered. These molecules often have specific functions and many of them have biological activities which can be of use to humans. They may provide lead compounds for the development of new drugs or they may be indispensable tools in biomedical research. While many are substrates for life processes, there are also toxins, hormones, and molecules with other functions. With the introduction of high-throughput screening protocols, there is the capacity to pass large numbers of compounds through a wide variety of bioassays. Since Nature's architecture provides such an unpredictable range of skeletal types and novel substances, it is of immense value to evaluate as many natural products as possible in order to find sources of new drugs [3] .
Over the past few years, there has been a considerable evolution of methodology and it is the aim of this review to give an insight into the techniques introduced and some future challenges.
New drugs derived from plant metabolites:
Over the last few decades, the field of anticancer drug research has involved a large amount of work on natural compounds. Thus, in the United States of America, more than 60% of the approved anticancer drugs between 1983 and 1994 were of natural origin [4] . Among them, several were either plant secondary metabolites or molecules derived from plant constituents. The diterpenoid paclitaxel (Figure 1 ), previously known as Taxol ® , was discovered as part of an NCI (National Cancer Institute)-sponsored program. It was isolated for the first time from the stem bark of the Pacific yew, Taxus brevifolia (Taxaceae), in the late 1960s, but has since been found in other yew species, such as the European yew T. baccata. Major supply problems have hampered, however, the development of this product and approval by the FDA was only obtained in 1992. While Taxol ® was initially used for the treatment of ovarian cancer resistant to chemotherapy, its therapeutic applications now include other gynaecological cancers, as well as lung cancer. Paclitaxel occurs almost exclusively in the stem bark of yews and at very low concentrations. Moreover, a total synthesis is not yet practicable on an industrial scale. The supply problem has been overcome by the development of a semisynthetic approach from 10-deacetylbaccatin II, a more accessible congener found in the needles of T. baccata. This strategy has also provided access to structural analogues, one of which, docetaxel (Taxotère ® ) has been recently commercialized.
Camptothecin derivatives are the most recent plantderived substances to be used in cancer therapy ( Figure 1 ). The monoterpenoid alkaloid camptothecin was isolated in the late 1960s from the Chinese ornamental tree Camptotheca acuminata (Nyssaceae). However, despite potent antitumour properties, the clinical success remained moderate owing to toxic effects and poor solubility. Considerable efforts have since been made to find more active and less toxic structural analogues. Topotecan (Hycamtin ® ) was approved in May 1996 by the FDA for the treatment of advanced ovarian cancers that resist other chemotherapy drugs ( Figure  1 ). In June 1996, injectable irinotecan-HCl was also approved for the treatment of metastatic cancer of the colon and rectum. Further plant-derived agents are currently under investigation for the treatment of cancer. Betulinic acid, a common constituent of birch trees (Betula spp., Betulaceae), for example, has been shown to exhibit potent antitumor activity. This metabolite is considered as a candidate of interest for the treatment of melanoma and other cancers.
In the last decade, plant products have also played a role in the development of new antimalarial agents, as illustrated by the discovery and development of artemisinin [5] . Artemisinin, a sesquiterpene lactone Because of the highly lipophilic nature of artemisinin, problems were encountered for its administration as a drug. A series of derivatives including ethers and carbonates have been synthesized. Among them, artemether, arteether and sodium artesunate are being licensed as drugs in an increasing number of countries. Artemisinin is also ideal for application with other antimalarials that have a longer span of action, such as the synthetic drug lumefantrine -in so-called Artemisinin Combination Therapy, ACT. The advantage of this approach is that two life cycles of the parasite are covered. One of the most efficient regimens is the artemether-lumefantrine combination (Coartem ® ).
Galanthamine (Figure 1 ), first isolated in the 1950s from Galanthus nivalis (Amaryllidaceae) [6] , is now one of the few therapeutics used in the management of Alzheimer's disease, by a mechanism involving maintenance of acetylcholine levels in the brain. Several randomized, double-blind, parallel group trials comparing galanthamine with placebo have examined the efficacy, the tolerability and the safety of the compound. Galanthamine maintains cognitive function, prevents the onset of newly occurring noncognitive behavioral symptoms for at least 1 year and delays the loss of activities of daily living by 6 months. Optimal therapy appears to require early initiation of the drug and a dosage-adjustment period of eight weeks.
The clinically-interesting alkaloid huperzine A ( Fig.ure 1) was originally isolated from the Chinese clubmoss Huperzia serrata (Lycopodiaceae) [7] . Huperzine A is a reversible inhibitor of acetylcholineesterase (AChE). The complex between huperzine and the enzyme dissociates rather slowly, which could explain its long duration of action. The compound is optically active and in nature only its (-)-enantiomer is present. The synthetic racemic mixture is 3 times less potent in vitro than the natural compound. A comparable effect is also observed in vivo. However, the racemic compound remains more potent than physostigmine in vitro. It was also shown to protect neurons against amyloid β−peptideinduced apoptosis. Several clinical trials have been reported in China and the efficacy of huperzine A was demonstrated in the treatment of 447 patients suffering from age-related memory dysfunction or dementia. The most frequently occurring side effects (dizziness, nausea and diarrhea) were related to its cholinergic properties. No liver and kidney toxicity was detected. A 5-chloro-vanilline derivative (ZT-1) of huperzine A is currently undergoing clinical trials in Switzerland. This derivative is used in the form of as an implant. A multicentre, randomized, doubleblind, placebo and active controlled phase II study with subcutaneous injections of the sustained release implants for the treatment of mild to moderate Alzheimer's disease is underway [8] .
Approaches for the discovery of new drugs from higher plants:
In order to find new drugs in plants, it is necessary to screen extracts for the presence of novel compounds and to investigate their biological activities. Once novel compounds are suspected, they are generally isolated in order to have material available for further biological and toxicological testing ( Figure 2 ).
The path, which leads from the intact plant to its pure constituents, is long. It involves work which might last anything from weeks to years. In order to rationalize and improve the efficiency of the approach, new strategies both in biological and chemical screening have to be developed in order to obtain valid chemical and bioactive information prior to the isolation work [9] .
Biological screening using simple bioautographic methods: In order to identify the active principle(s) of a given plant, access to bioassays that will reveal the mode of action of a given natural product is mandatory. The choice of the correct therapeutic target can, however, be complex since the key enzymes involved in a disease have to be identified. In a phytochemical laboratory it is impossible to have access to all targets and the choice of bioassays has to be restricted to relatively simple and sensitive systems that then bring a rather general idea of the type of activity expected. These types of assays can typically be performed on lower organisms, invertebrates and isolated subcellular systems.
At the Laboratory of Pharmacognosy and Phytochemistry (LPP) in Geneva, for example, the array of assays includes tests for antifungal, antibacterial, molluscidical, insecticidal, larvicidal and antioxidant activities, as well as inhibition of key enzymes such as acetylcholinesterase (AChE). In order to obtain a rapid localization of active natural products directly on TLC, which is important to speed up the isolation process, efforts have been made particularly in the development of bioautography methods [10] . With such methods, the crude extracts, fractions or pure constituents are resolved on TLC and the organisms or reagents are applied to the TLC plate. Zones of inhibition can be visualized directly on the TLC, thus revealing the activity. This type of technique has been successfully used for screening antifungal agents inhibiting the growth of a phytopathogenic fungus Cladosporium cucumerinum or the human pathogenic yeast Candida albicans [11] .
In the search for new compounds that can be relevant in the pharmacological management of Alzheimer's disease, a bioautographic enzyme assay using AChE has been recently developed [12] . In this test, the enzyme hydrolyses a substrate (α-naphthyl actetate) and the resulting moiety (α-naphthol) is detected as an azo dye. In the presence of enzyme inhibitors, no hydrolysis occurs and white spots are observed on the TLC plate. The discovery of bioactivities of extracts and/or fractions by these simple assays is a very useful first step in the process which leads to new pharmacophores. This preliminary data must of course be followed up by more thorough in vitro and in vivo testing, but the benchtop bioassays are of great value for guiding the whole pathway from the plant to pure new lead compounds.
Chemical screening with hyphenated techniques:
One major drawback of the bioassay-guided fractionation strategy is the frequent re-isolation of known metabolites. The chemical screening of crude extracts therefore constitutes an efficient complementary approach allowing localisation and targeted isolation of new types of constituents with potential activities. This procedure, known as dereplication, also enables recognition of known metabolites at the earliest stage of separation, thus avoiding a time-consuming and costly isolation of common constituents.
Chemical screening is most effectively performed by means of LC/UV-DAD, LC/MS and LC/NMR of crude plant extracts ( Figure 2) [13] . The dereplication procedure generally proceeds in two steps. The crude plant extracts exhibiting an interesting bioactivity are first analysed by LC/UV/MS and if complementary structural information is required, de novo structure elucidation can be performed by LC/NMR. Using such a bidimensional screening approach, it is possible to isolate numerous lead compounds. In one instance, as part of a programme to find potential therapeuticals from European plants for the management of Alzheimer's disease, several inhibitors of AChE have been isolated from the mountain plant called masterwort [Peucedanum ostruthium (Apiaceae)]. Fractionation of the crude CH 2 Cl 2 extract of the roots by centrifugal partition chromatography (CPC) afforded six compounds, final purification of which was by either crystallisation or a second CPC step. The pure compounds were then tested against AChE using the bioautographic assay. Solutions of pure compounds were applied on the TLC plate in a quantity of 1 µg. All the molecules gave an inhibition spot after spraying with enzyme and substrate. Dilutions were then made in order to find the minimum quantity required to produce white inhibition spots. It was shown that the coumarins were more active than the chromone derivative peucenin. Moreover, in this bioassay, ostruthol, the most active of the four tested coumarins, was about ten-fold more active than the AChE inhibitor galanthamine, and almost as strong as huperzine A (from Huperzia serrata, Lycopodiaceae), which is for the moment the most powerful AChE inhibitor [14] .
The methanol extract of Gentiana campestris (Gentianaceae) leaves also exhibited significant inhibition of AChE in the TLC bioassay. A bioactivity-guided fractionation approach was undertaken to isolate the active components, using semi-preparative HPLC. Four xanthones, bellidin, bellidifolin, bellidin-8-O-glucoside (norswertianolin), and bellidifolin-8-O-glucoside (swertianolin) ( Figure  4 ), were found to be responsible for the anti-AChE effects. A quantity of 1 µg of each xanthone deposited on the TLC plate gave an inhibition spot after spraying with enzyme and substrate. Dilutions were then made in order to find the minimum quantity required to produce white inhibition spots. It was found that all xanthones inhibited the enzyme at less than 0.5 µg. The most active compound, bellidifolin, showed similar activity (inhibition down to 0.01 µg) as that of galanthamine in this enzyme assay [15] .
A dichloromethane extract of Monotes engleri (Dipterocarpaceae) was investigated for its antifungal properties [16] . In this case the antifungal activity could be linked to the main constituent (10) detected in the HPLC/UV chromatogram ( Figure 5 ).
The UV spectrum of this compound was characteristic of a flavanone and its LC/TSP-MS spectrum showed a protonated molecule [M+H] + at m/z 357, which exhibited a loss of 68 Da ([M+H-C 4 H 8 ] + ), due to an O-prenyl substituent ( Figure 5 ).
Based on these data and according to the molecular weight of a flavanone skeleton, it could be deduced that 10 was most probably a flavanone with one Oprenyl unit and three hydroxyl substituents. In order to ascertain the on-line structure assignments made for this compound, a stop-flow LC/ 1 H-NMR experiment was performed on the LC/peak of interest in an enriched fraction ( Figure 5 ).
Interpretation of the signals recorded in the stop-flow LC/ 1 H-NMR confirmed that 10 was a prenylated flavanone. Two methylene protons at δ 2.9 and δ 3.2 ppm suggested the presence of a γ-dihydropyrone ring. The deshielded doublet for the methylene of the prenyl unit at δ 4.7 ppm confirmed the O-connection of the prenyl unit, as deduced from the LC/MS data. These data were, however, not sufficient for a complete identification, and the position of the prenyl unit could not be deduced. 2D-stop-flow LC/NMR correlation experiments were thus performed. In the stop-flow mode, 1 H -1 H correlations such as COSY or NOESY can be measured and information on 13 C can be extracted from 1 H- 13 C correlation experiments, such as HSQC and HMBC, provided that the quantity of compound is high enough (typically >100 µg for a 500 MHz instrument). The LC/GDQCOSY (gradient double quantum filtered COSY) confirmed the coupling of the different protons, especially between H-2 and H-3 in the C-ring and H-1" and H-2" on the prenyl chain. The LC/GHSQC (gradient heteronuclear single quantum coherence) showed all C-H connectivities. In the LC/GHMBC (gradient heteronuclear multiple quantum coherence), the longrange couplings of the γ-dihydropyrone ring were visible and the position of the prenyl unit on the Bcycle could be determined. The combination of the data obtained with these two inverse 1 H- 13 C correlation experiments allowed assignment of all the 13 C resonances of 10 on-line, directly in the LC eluent. The recording of these data was, however, possible only because of the very high concentration of 10 in the LC/NMR flow cell. In order to determine the exact position of the prenyl unit on the flavanone skeleton of 10, a 2-D LC/WET-NOESY (2-D Nuclear Overhauser Effect) experiment was run. The sensitivity was good enough for the observation of clear NOE effects. However, the weak resolution of the 1 H-pattern of the B-cycle in the MeCN: D 2 O solvent system did not permit the differentiation of H-2' and H-5', preventing the full structural assignment of 10. A second stop-flow LC/NMR analysis of the active fraction was then performed in MeOH: D 2 O. In this latter solvent system, the three aromatic protons of the B-cycle were observed at distinct chemical shifts. Two doublets (J = 7.8 Hz) at δ 6.90 and δ 6.95 were attributable to the orthocoupled protons H-6' and H-5', and one broad singlet at δ 6.97 was due to H-2'. A second WET-NOESY was performed in this latter solvent system. First, an irradiation of H-2 gave enhancement of the two H-2' and H-6' aromatic protons at δ 6.97 and δ 6.90. A correlation with the H-2 and the two protons on C-3 was also shown.
Secondly, irradiation of H-1" gave enhancement of the ortho-coupled proton at δ 6.95 (H-5'). Other NOE effects were also measured on the prenyl unit, 
Killing cancer by light:
There are other methods of utilization of natural products in the therapy of diseases. One of these involves light.
Certain plants produce photosensitization in animals. When grazing, the animals ingest these plants and begin to suffer from light sickness when exposed to radiation, especially in the 540-610 nm range. The symptoms include skin efflorescence in the form of blisters and psychomotor excitement. The phenomenon of photosensitization has been exploited recently in the therapy of two diseases: cancer and age-associated macular degenerescence (AMD).
Photodynamic therapy (PDT) has been described as a promising new modality for the treatment of cancer. PDT involves the combination of a photosensitizing agent (photosensitizer), which is preferentially taken up and retained by tumor cells, and visible light of a wavelength matching the absorption spectrum of the drug. Each of these factors is harmless by itself, but when combined they ultimately produce, in the presence of oxygen, cytotoxic products that cause irreversible cellular damage and tumor destruction. This forms the basis of the therapy with HPD (Visudyne ® ) in cancers.
Hypericin, a powerful naturally-occurring photosensitizer, is found, together with pseudohypericin ( Figure 6 ), in Hypericum perforatum (Hypericaceae), commonly known as St. John's wort. In recent years increased interest in hypericin as a potential clinical anticancer agent has arisen since several studies have established its powerful in vivo and in vitro antineoplastic activity upon irradiation. Investigations of the molecular mechanisms underlying hypericin photocytotoxicity in cancer cells have revealed that this photosensitizer can induce both apoptosis and necrosis in a concentration-and light dose-dependent fashion. Moreover, PDT with hypericin results in the activation of multiple pathways that can either promote or counteract the cell death program.
Hypericin has been proposed for the detection and treatment of ovarian and bladder cancer, using a photodynamic therapy approach. Due to its hydrophobicity, systemic administration of hypericin is problematic. Thus, polymeric nanoparticles of polylactic acid or polylactic-co-glycolic acid were used as a drug delivery system [18] .
Prodrugs, an unexploited source of interesting compounds to be explored: It is true to say that the anti-inflammatory and analgesic compound salicylic acid (and thus the semi-synthetic derivative aspirin) would not have been discovered in the present style of biological testing and high throughput screening protocols. These rapid techniques are not geared to take into account the metabolism of plant constituents and thus miss the presence of compounds in prodrug form which need activation to produce the required bioactivity. Salicin occurs in the bark of willow (Salix, Salicaceae) species, but requires deglucosylation and oxidation in the human body before the active entity, salicylic acid, is formed (Figure 7) .
Another example is the phenolic glucoside arbutin, which is found in the bearberry leaf (Arctostaphylos uva-ursi, Ericaceae). Arbutin is hydrolyzed and oxidized to hydroquinone (Figure 8 ) in the human body and then excreted in the form of a glucuronide or a sulfate. The presence of hydroquinone is essential for the treatment of urinary tract infections and in order to have sufficient concentrations (> 60 µg/mL), the urine must be alkaline to allow hydrolysis of the conjugates. Sennosides are glycosides of dianthrones and are found in the dried leaves of Cassia angustifolia and C. senna (Leguminosae). On ingestion of the herb drug, the inactive sennosides are converted into laxative anthrones by bacteria in the gut. Furthermore, only non-conjugated forms of phytoestrogens (such as isoflavonoids) can exert estrogen-like activity in animals. Thus, the aglycones have to be liberated by hydrolysis in the stomach or the gut before their effects can be felt [19] .
These examples show that in order to exploit Nature's full diversity, an initial activation step is required for many natural products. As well as a classical screening procedure, therefore, the search for new compounds should also include a metabolic simulation with the plant extracts under investigation before studying the bioactivity. This can take the form of a hydrolysis or oxidation step, for instance, and there are many other steps to be looked at.
Conclusion:
Plants still represent a huge reservoir of interesting bioactive lead compounds for the development of therapeuticals. In order to valorise this potential and accelerate the bioactivity-guided isolation process, advanced screening procedures involving both biological and chemical aspects have continually to be developed.
These techniques will also improve the quality and safety control of herbal preparations and precise metabolite profiling of the extracts will become possible. Among the new and exciting challenges that await phytochemists, it is safe to assume that these screening strategies will take an increasingly active part in the discoveries that have yet to be made in natural products chemistry.
